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Background. HLA genes play a role in the predisposition of several diseases. The aim was to analyze the prevalence of HLA class I
phenotypes and HLA-DRB1
￿ genotype in patients with CIU associated with ASA and NSAIDs hypersensitivity (AICU). Methods.
69 patients with AICU, and 200 healthy subjects. Results. Subjects with HLA-B44 and HLA-Cw5 antigens were more represented
in patients with AICU than in control group. Subjects with HLA-A11, HLA-B13, HLACw4, and HLA-Cw7 antigen were more
represented in control group than in patients with AICU. Multiple logistic regression demonstrated an association of HLA-Cw4
and HLA-Cw7 with a lower risk of AICU, whereas carriers of HLA-B44 phenotype had a higher risk of AICU. No diﬀerences were
found between patients and controls as regards to HLA-DRB1
￿ genotype. Conclusions. We observed an association between some
HLA class-I antigens and AICU. To the best of our knowledge this is the ﬁrst description of such association.
Copyright © 2006 Maria Luisa Pacor et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Urticaria is a common skin disorder characterized by erythe-
matous, raised skin lesions, usually intensely itching, lasting
less than 24 hours, or occasionally even longer. By deﬁni-
tion, urticaria of < 6 weeks duration is arbitrarily consid-
ered“acute,”whereasurticariarecurring> 6weeksisreferred
to as “chronic.” Generally, 40 to 60% of the patients with
chronic urticaria do not have a well-described cause (“ordi-
nary” chronic idiopathic urticaria) [1, 2].
In approximately 60% of patients with chronic urticaria
it has been demonstrated that intradermal injection of au-
tologous serum causes a weal and ﬂare response typical of
an urticarial lesion, due to the presence of IgG antibodies
directed to the α subunit of the high aﬃnity IgE receptor
(Fc
￿ = εRI) on mast cell and basophils (autoreactive chronic
urticaria). In other patients, aspirin and/or nonsteroidal
anti-inﬂammatory drugs (NSAIDs) and/or food additives
hypersensitivity can aggravate urticaria. However, in many
patients the mechanisms causing their urticaria remain ob-
scure [3–5].
The human leucocyte antigen (HLA) genes play a ma-
jor role in regulating the immune response. HLA class-I and
class-II molecules are membrane-bound glycoproteins that
bind intracellularly processed antigenic peptides and present
them to T cells via T-cell receptors and are encoded by the
most highly polymorphic gene family in the human genome
[6]. HLA class-I molecules are present on all nucleated cells
and platelets and present peptides of endogenous origin to
CD8+ T cells, while HLA class-II molecules are expressed on
a more restricted range of cell types—including B cells, ac-
tivated T cells, and the monocyte/macrophage lineage—and2 Mediators of Inﬂammation
present short peptides of exogenous origin to CD4+ T cells,
mainly withhelperphenotype. Therefore,polymorphisms of
the HLA molecules can modulate the capacity to bound and
present diﬀerent peptides [7].
HLA loci play a well-known role in predisposition to sev-
eral and diﬀerent diseases, including rheumatoid arthritis,
ankylosingspondylitis,coeliacdisease,insulin-dependentdi-
abetes mellitus, multiple sclerosis, atopic disease, and food
allergy [8]. Mainly HLA type-II polymorphisms have been
associated with such diseases, but also the HLA type-I locus
has been found in relation with some pathologies (ie, HLA-
B27 and ankylosing spondylitis) [9].
The aim of our study is to analyze the prevalence of HLA
class-I phenotypes (HLA A, B, Cw) and HLA-DRB1
￿ geno-
type in blood from patients aﬀected by chronic idiopathic
urticaria associated with aspirin and/or NSAIDs hypersensi-
tivity (AICU).
MATERIALS AND METHODS
Patients
A total of 69 patients (16 males, 53 females; mean age 42.3
￿
16.2y e a r s ) ,a ﬀected by AICU, living in North-East Italy, were
selected from the outpatient clinic of the Dipartimento di
Medicina Clinica, Universit` a di Verona (Italy). AICU was de-
ﬁnedasthepresenceofurticariallesionsrecurring>6weeks,
exacerbatedbytheadministrationofaspirinand/orNSAIDs,
withoutanyotherknownsecondarycauses.Inallpatientswe
performed a speciﬁc challenge with oral acetylsalicylic acid
(ASA) (see below). The presence of urticarial skin lesions,
with or without angioedema, was clinically conﬁrmed in all
patients. Our institutional policy and the ethical committee
in our institution do not require that an ethics committee
authorize the study. However, institutional policy requires
the patient’s written informed consent for us to perform the
study; we obtained consent in every case. The study was car-
ried out during the period between January 2002 and De-
cember 2003.
Patients with physical urticaria, positive skin test to au-
tologous serum, or food additives hypersensitivity were ex-
cluded from the study [10–13]. The control group was rep-
resented by 200 healthy subjects, enrolled in the bone mar-
row donors register (97 males, 103 females; mean age 29.9
￿
4.9 years), from the same geographic region, sex- and age-
matched. No subject of the control group was aﬀected by
atopic/allergic diseases and/or acute or chronic urticaria.
Oralacetylsalicylicacidchallenge
All patients performed a double-blind, placebo-controlled
challenge (DBPC) with ASA. For the DBPC we used ASA
and placebo. They were in gelatin capsule (LoFarma, Milan,
Italy). None of the patients presented urticaria symptoms
at the time of testing. Antihistamines had been interrupted
3 days before the challenges. An informed consent was ob-
tained from all the subjects. Challenges were administered
using a double-blind placebo-controlled procedure during
the morning hours. Before DBPC, patients received a sham-
challenge with placebo (talc). When no urticaria symptoms
were noted after placebo, 1 hour later, DBPC was performed
using ASA and placebo. They were given in a randomized
sequence: three placebo capsules and three doses of ASA
(10mg, 10mg, and ﬁnally 20mg). Each dose was given af-
ter 1 hour, if no symptoms had developed with the previous
administration. Only the appearance of unequivocal wors-
ening of urticaria (deﬁned as pruritic and erythematous ar-
eas raised over normal skin) and/or the appearance of an-
gioedema (deﬁned as swelling of the skin and/or external
mucosa) were considered as a positive response [11–13].
HLAclass-IphenotypeandHLA-DRB1
￿ genotype
HLA class-I antigens were typed by serology with human an-
tisera using the standard complement-dependent microlym-
phocytotoxicity assay, using a panel of 100 lymphocytes. The
antisera used for typing locus A were 1, 2, 3, 9, 10, 11, 23, 24,
25, 26, 28, 29, 30, 31, 32, 33, 34, 35, 37, 40, 43, 66, 68, 69, 74;
for typing locus B 5, 7, 8, 12, 13, 14, 15, 16, 17, 18, 21, 22, 23,
27, 37, 38, 39, 40, 41, 42, 44, 45, 46, 47, 49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 60, 61, 62, 63, 64, 65, 70, 71, 72, 73, 75, 76, 77;
for typing locus Cw 1, 2, 3, 4, 5, 6, 7, 8, 17.
DNA was prepared from ethylenediamine tetraacetic
acid-anticoagulatedblood.Asalting-outmethodwasusedto
extract genomic DNA, which was then precipitated, washed
with ethanol, and resuspended in water. Then, for each sam-
ple,HLAclass-IIgenotypingwasperformedforHLADRB1
￿,
evaluating the 1, 3, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, and
17 alleles, by using a “low-resolution” polymerase chain re-
action ampliﬁcation with sequence-speciﬁc primers (PCR-
SSP) (Olerup Low-Resolution Kit).
Statisticalmethods
Data were analyzed with SPSS 13.0 statistical package (SPSS
Inc, Chicago, Ill). Quantitative data were assessed with Stu-
dentt test.Associationsbetweenqualitativevariables,suchas
prevalenceofHLAphenotypesandgenotype,inpatientsand
control groups, were analyzed with χ2-test or Fisher-exact
test when indicated. Statistical signiﬁcance was set at P val-
ues smaller than .05. To better evaluate the potential associ-
ation between HLA phenotypes and genotype and AICU, we
alsoperformedamultiplelogisticregressionanalysis,includ-
ing all the HLA phenotypes and genotype with a signiﬁcant
diﬀerent distribution in the univariate analysis. To assess the
strength of these associations, odds ratios (OR), with 95%
conﬁdence interval (95% CI), were calculated.
RESULTS
The frequency of HLA class-I phenotypes and HLA-DRB1
￿
alleles in patients with AICU and in the control group is
shown in Tables 1(a)-1(b).
In our population, 6 HLA class-I antigens presented a
signiﬁcantly diﬀerent distribution between patients and con-
trols; whereas no signiﬁcant diﬀerence was found for the
HLADRB1
￿ alleles distribution. Subjects with HLA-B44Maria Luisa Pacor et al 3
Table 1: (a)–(d):HLA class-I (A,B, and Cw)phenotypes and HLA-
DRB1
￿ genotypes in patients aﬀected by AICU and in the control
group.
Control group CIU AICU group P (n = 200) (n = 69)
HLA-A
(phenotype carrier)
12 1 .0% 23.2% NS
￿
24 8 .5% 52.2% NS
31 8 .5% 24.6% NS
90 % 0 % N S
10 0.5% 0% NS
11 13.0% 4.3% .046
23 6.0% 2.9% NS
24 32.5% 26.1% NS
25 2.5% 7.2% NS
26 8.0% 5.8% NS
28 0.5% 4.3% NS
29 2.0% 2.9% NS
30 7.5% 2.9% NS
31 6.5% 2.9% NS
32 8.0% 5.8% NS
33 4.5% 5.8% NS
34 0 % 0 % NS
35 0 % 0 % NS
37 0 % 0 % NS
40 0 % 0 % NS
43 0 % 0 % NS
66 0.5% 0 % NS
68 9.5% 11.6% NS
69 0 % 2.9% NS
74 0 % 0 % NS
(a)
HLA-B Control group CIU AICU P (phenotype carrier) (n = 200) group (n = 69)
50 % 0 % N S
71 3 .5% 11.6% NS
81 3 .5% 5.8% NS
12 0% 0% NS
13 9.5% 0% .005
14 1.5% 0 % NS
15 2.0% 0 % NS
16 0.5% 0 % NS
17 2.0% 1.4% NS
18 17.0% 23.2% NS
21 0 % 0 % NS
22 0 % 0 % NS
23 0 % 1.4% NS
27 6.0% 7.2% NS
35 29.0% 24.6% NS
37 3.0% 4.3% NS
38 4.5% 4.3% NS
39 8.0% 4.3% NS
40 2.5% 0 % NS
41 0.5% 4.3% NS
4 2 0% 0% N S
44 13.0% 29.0% 0.002
45 1.0% 1.4% NS
(b)
HLA-B Control group CIU AICU P (phenotype carrier) (n = 200) group (n = 69)
46 0% 0% NS
47 1.0% 1.4% NS
49 7.5% 7.2% NS
50 6.0% 1.4% NS
51 20.5% 23.2% NS
52 1.0% 0% NS
53 2.0% 2.9% NS
54 0 % 0% NS
55 4.0% 2.9% NS
56 1.0% 1.4% NS
57 8.5% 2.9% NS
58 3.0% 4.3% NS
60 3.5% 2.9% NS
61 0.5% 0 % NS
62 6.0% 8.7% NS
63 1.0% 1.4% NS
6 4 0% 0% N S
65 1.5% 4.3% NS
7 0 0% 0% N S
7 1 0% 0% N S
7 2 0% 0% N S
73 0.5% 0 % NS
75 0.5% 0 % NS
7 6 0% 0% N S
7 7 0% 0% N S
(b) Continued.
HLA-Cw Control group CIU AICU group P (phenotype carrier) (n = 200) (n = 69)
19 .0% 5.8% NS
28 .5% 11.6% NS
31 6 .0% 8.7% NS
4 37.0% 14.5% .001
5 5.5% 14.5% .016
61 7 .5% 8.7% NS
7 48.5% 23.2% <.001
80 % 1 .4% NS
17 1.0% 0 % NS
(c)
HLA-DRB1
￿ Control group CIU AICU group P (allele carrier) (n = 200) (n = 69)
11 6 .0% 15.9% NS
32 1 .0% 14.5% NS
41 5 .5% 10.1% NS
72 4 .0% 26.1% NS
87 .5% 4.3% NS
91 .0% 0 % NS
10 3.5% 0 % NS
11 39.5% 44.9% NS
12 6.5% 4.3% NS
13 22.0% 26.1% NS
14 7.5% 11.6% NS
15 15.5% 8.7% NS
16 12.0% 8.7% NS
17 1.0% 0 % NS
(d)
￿ By χ2 test or Fisher’s exact test; NS: not signiﬁcant.4 Mediators of Inﬂammation
antigen were more represented in patients aﬀected by AICU
than in control group (29% versus 13%; P = .002), as
well as subjects with HLA-Cw5 antigen (14.5% versus 5.5%;
P = .016). On the other hand, subjects with HLA-A11 (4.3%
versus 13%; P = .046), HLA-B13 (0% versus 9.5%; P =
.005), HLA-Cw4 (14.5% versus 37%; P = .001), and HLA-
Cw7 antigen (23.2% versus 48.5%; P<. 001) were more rep-
resented in control group than in patients aﬀected by AICU.
Then we performed a multiple-logistic regression, includ-
ing all the above-mentioned HLA antigens; only three HLA
phenotypes maintained a signiﬁcant diﬀerent distribution,
more precisely, HLA-Cw4 (OR 0.18 with 95% CI 0.08–0.40;
P<. 001) and HLA-Cw7 (OR 0.21 with 95% CI 0.11–0.42;
P<. 001) remained associated with a lower risk of AICU,
whereas carriers of HLA-B44 phenotype had a higher risk of
AICU (OR 2.63 with 95% CI 1.13–6.12; P = .024).
DISCUSSION
In this study we demonstrated an association between some
HLA class-I antigens and chronic idiopathic urticaria asso-
ciated with aspirin and/or NSAIDs hypersensitivity (AICU).
Inparticular,twoHLA-Cwphenotypes,HLA-Cw4andHLA-
Cw7,seemtobelessfrequentinpatientswithAICU,whereas
HLA-B44 shows a positive association with this subtype of
chronic urticaria. To the best of our knowledge, this is the
ﬁrst description of such association.
Many studies have investigated the etiology of chronic
urticaria. Recent researches have focused primarily on the
demonstration of IgG antibodies directed to the α subunit
of the high aﬃnity IgE receptor (FcεRI) on mast cell and ba-
sophils, revealed by autologous serum skin test, and on the
copresence of aspirin and/or NSAIDs and/or food additives
hypersensitivity aggravating urticaria. However, in many pa-
tients, the exact mechanisms governing regional mast cell or
basophilactivationareunknown;thisconditionisusuallyin-
dicatedbythetermof“ordinarychronicidiopathicurticaria”
[1, 2].
Besides,manyquestionsstillremaintobeanswered,such
as the triggering of the autoreactive process, other immu-
nological or not immunological pathogenetic mechanisms,
temporary spontaneous remissions, and genetic heterogene-
ity of the patients [3–5].
gKim et al suggested that some HLA class-II genotypes
are a strong genetic marker to determine the aspirin-induced
urticaria phenotype [14]. However, the data have not been
conﬁrmed by other studies [15, 16]. The HLA class-I loci, at
thistime,arerelativelylessinvestigatedthanHLAclass-IIloci
in reference to disease predisposition. Therefore, HLA class-I
antigen plays a major role in ankylosing spondylitis [9]. Nev-
ertheless, it is interesting to emphasize that some HLA class-
I alleles have been reported to be associated with adverse
events in patients taking various drugs: HLA-A29 and B12
with Stevens-Johnson syndrome induced by sulphonamide,
HLA-A2 and B12 with Stevens-Johnson syndrome induced
by NSAIDs [17, 18]. Recently, the HLA-B
￿5801 allele has
been proposed as a genetic marker for severe cutaneous ad-
verse reactions caused by allopurinol [19].
Furthermore and interestingly, new functions, that could
play a role in pathogenetic processes, have been identiﬁed for
HLA class-I molecules, mainly for HLA-Cw, such as the in-
hibition of the lytic capacity of natural killer cells and non-
M H Cr e s t r i c t e dTc e l l s[ 20].
It is now tempting to speculate that some of HLA class-
I molecules could be involved in some of the heterogeneous
pathogenetic mechanisms of AICU and, consequently, that
HLA variants could induce this subtype of chronic urticaria.
In conclusion, we assume that HLA alleles may be in-
volved in the development of AICU as possible predisposing
factors.
ABBREVIATIONS
HLA human leucocyte antigen
NSAIDs nonsteroidal anti-inﬂammatory drugs
AICU chronic idiopathic urticaria associated with
aspirin and/or NSAIDs hypersensitivity
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